293480.KO Hana Pharm Co Ltd
- Market cap
- KRW 144B
- P/E
- 6.0x
- P/B
- 0.44x
- ROE
- 11.1%
- Dividend yield
- 6.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 293480.KO undervalued?
Graham number293480.KO trades 66.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hana Pharm Co Ltd fundamental analysis
No fundamental analysis for Hana Pharm Co Ltd yet.
Hana Pharm Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hana Pharm Co Ltd
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1996 and is headquartered in S…
Full company profileHana Pharm Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hana Pharm Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 125B | 139B | 153B | 166B | 177B | 196B | 211B | 224B | 225B | 240B | 246B |
| Gross Profit | 83.9B | 94.4B | 102B | 110B | 114B | 131B | 131B | 140B | 141B | 145B | 153B |
| Operating Income | 23.7B | 31.9B | 33.6B | 33.6B | 31.7B | 36.0B | 31.2B | 27.0B | 25.2B | 25.8B | 28.8B |
| EBITDA | - | 35.5B | 36.2B | 39.1B | 33.5B | 41.7B | 37.8B | 34.7B | 32.9B | 37.0B | 42.5B |
| Net Income | 17.4B | 24.3B | 26.2B | 28.3B | 14.9B | 28.0B | 24.3B | 22.3B | 21.3B | 8.78B | 36.9B |
| EPS | - | 1,364 | 1,478 | 1,636 | 861 | 1,619 | 1,405 | 1,291 | 1,228 | 495 | 2,083 |
| Balance Sheet | |||||||||||
| Total Assets | 115B | 142B | 242B | 263B | 277B | 303B | 346B | 348B | 382B | 418B | 447B |
| Total Liabilities | 59.1B | 60.3B | 37.0B | 42.7B | 44.2B | 51.6B | 77.6B | 70.4B | 72.8B | 105B | 115B |
| Shareholders' Equity | 55.5B | 80.9B | 205B | 220B | 232B | 252B | 268B | 278B | 309B | 313B | 332B |
| Cash & Short-term Investments | 1.39B | 12.9B | 17.0B | 15.0B | 20.5B | 6.62B | 12.5B | 1.42B | 8.52B | 9.84B | 12.4B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 12.5B | 25.4B | 27.6B | 31.7B | 15.6B | 25.7B | 30.9B | 18.4B | 25.3B | 9.18B | 30.3B |
| Capital Expenditure | 8.31B | 10.2B | 5.57B | 33.7B | 17.1B | 34.8B | 35.8B | 14.7B | 13.2B | 31.2B | 103B |
| Free Cash Flow | - | 21.5B | 22.0B | -2.01B | -1.56B | -9.16B | -4.89B | 3.72B | 12.1B | -22.0B | -72.6B |
| Ratios | |||||||||||
| ROE | 31.4% | 30.0% | 12.7% | 12.8% | 6.4% | 11.1% | 9.1% | 8.0% | 6.9% | 2.8% | 11.1% |
| ROA | 15.2% | 17.2% | 10.8% | 10.8% | 5.4% | 9.2% | 7.0% | 6.4% | 5.6% | 2.1% | 8.3% |
| Net Profit Margin | 14.0% | 17.4% | 17.1% | 17.0% | 8.4% | 14.3% | 11.5% | 9.9% | 9.4% | 3.7% | 15.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Hana Pharm Co Ltd dividends
- Dividend yield
- 6.12%
- Forward dividend
- 260.00 KRW
- Payout ratio
- 100.5%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 8.82B | 498 | 100.5% |
| 2024 | KRW 8.82B | 510 | 41.5% |
| 2023 | KRW 8.82B | 510 | 39.5% |
| 2022 | KRW 8.82B | 510 | 36.3% |
| 2021 | KRW 8.02B | 464 | 28.6% |
| 2020 | KRW 7.24B | 418 | 48.6% |
| 2019 | KRW 4.51B | 261 | 15.9% |
| 2018 | KRW 3.01B | 170 | 11.5% |
| 2017 | KRW 1.02B | 57 | 4.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.1:1 on Apr 28, 2021.
Who owns Hana Pharm Co Ltd
- Insiders 60.72%
- Institutions 0.33%
- Public & others 38.95%
- Shares outstanding 17.7M
- Free float 4.28M
Hana Pharm Co Ltd company profile
- Company name
- Hana Pharm Co Ltd
- Ticker
- 293480.KO
- ISIN
- KR7293480000
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- EK-Tower, Seoul, South Korea, 06162
- Phone
- 82 2 577 7667
- Website
- hanaph.co.kr
About Hana Pharm Co Ltd
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and anti-inflammatory drugs. The company was founded in 1996 and is headquartered in Seoul, South Korea.
Hana Pharm Co Ltd management
4- Taehong ChoiPresident, CEO & Director
- Hong-Joo YunDirector of Business Department, CFO & Director
- Elia ChoDirector of Global Department & Director
- Sang-yeop KimHead of New Product Research Lab